Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Catalyst Grant: HIV/AIDS Vaccine Discovery Research (Can HIV Vaccine Initiative)

Université Laval

$100,000.00

Promoting innate immunity to HIV infection by vaccine delivery of third generation RNA analogs

EF 2008-09

Résumé
Infection by the human immunodeficiency virus (HIV) can lead to a progressive deterioration of the body's immune system. AIDS (Acquired Immunodeficiency Syndrome) represents the stage when a HIV-infected individual's life is threatened by common pathogens that are normally destroyed by the immune system of healthy individuals. HIV is a retrovirus that has evolved to circumvent the human immune system in such ways that no cure or vaccine has yet been successfully developed. One of the virus' survival strategies is to cripple conventional adaptive immune responses that are essential for the effectiveness of most vaccines because the cells of the immune system themselves are its target. Nevertheless, there are several endogenous factors that can protect humans against the spread of HIV infection. One of these antiviral factors is a protein called APOBEC3G that is part of the innate component of the immune system. This protein can bind and heavily mutate HIV DNA, ultimately leading to the inactivation and destruction of the virus. Unfortunately, HIV encodes a protein called Vif that is dedicated to specifically induce the degradation of APOBEC3G. The overall aim of this catalyst grant proposal is to validate a new Vif-inhibiting technology that could lead to the development of a vaccine that could induce the inactivation infectious HIV particles in HIV/AIDS patients and also promote the elimination of HIV infected cells by recruiting the intrinsic antiviral properties of the innate immune system.
Programme
Catalyst Grant: HIV/AIDS Vaccine Discovery Research (Can HIV Vaccine Initiative)
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
174607
Name
Langlois Marc-Andre
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
HIV Vaccine Discovery
Projecttitle
Promoting innate immunity to HIV infection by vaccine delivery of third generation RNA analogs
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Catalyst Grant: HIV/AIDS Vaccine Discovery Research (Can HIV Vaccine Initiative)
Keyworddelim
Apobec3g; Hiv; Locked Nucleic Acids; Vif
Abstract
Infection by the human immunodeficiency virus (HIV) can lead to a progressive deterioration of the body's immune system. AIDS (Acquired Immunodeficiency Syndrome) represents the stage when a HIV-infected individual's life is threatened by common pathogens that are normally destroyed by the immune system of healthy individuals. HIV is a retrovirus that has evolved to circumvent the human immune system in such ways that no cure or vaccine has yet been successfully developed. One of the virus' survival strategies is to cripple conventional adaptive immune responses that are essential for the effectiveness of most vaccines because the cells of the immune system themselves are its target. Nevertheless, there are several endogenous factors that can protect humans against the spread of HIV infection. One of these antiviral factors is a protein called APOBEC3G that is part of the innate component of the immune system. This protein can bind and heavily mutate HIV DNA, ultimately leading to the inactivation and destruction of the virus. Unfortunately, HIV encodes a protein called Vif that is dedicated to specifically induce the degradation of APOBEC3G. The overall aim of this catalyst grant proposal is to validate a new Vif-inhibiting technology that could lead to the development of a vaccine that could induce the inactivation infectious HIV particles in HIV/AIDS patients and also promote the elimination of HIV infected cells by recruiting the intrinsic antiviral properties of the innate immune system.
Competitiondate
200811
Approvedterm2
1 yr 0 mth
Pinamesdelim
Langlois, Marc-Andre
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~